Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

TNKase tenecteplase: Marketed in U.S.; under review in Europe

August 27, 2001 7:00 AM UTC

Patients given TNKase plus Clexane had an event rate of 13.75% compared to 17.04% for TNKase and UFH (p=0.0081). The TNKase plus UFH and ReoPro group had an event rate of 14.24%, which was lower than ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article